TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Polynovo ( (AU:PNV) ) has provided an update.
PolyNovo Limited announced promising results from a randomized controlled trial evaluating its NovoSorb BTM product for post-surgical diabetes-related foot wounds. The study demonstrated that NovoSorb BTM significantly accelerates healing of large wounds compared to standard care, reducing the time to complete healing by over four months. This positions NovoSorb BTM as a valuable option in the limited treatment landscape for diabetic foot wounds, potentially influencing outpatient adoption and treatment practices, especially in the U.S. if CMS pricing changes in 2026.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in the management of acute complex wounds. The company is known for its innovative products that redefine healing and improve patient outcomes across various wound types. With a presence in 46 countries and over 84,000 patients treated, PolyNovo is focused on growth through new products, indications, and markets.
Average Trading Volume: 2,677,259
Technical Sentiment Signal: Sell
Current Market Cap: A$967.2M
See more insights into PNV stock on TipRanks’ Stock Analysis page.